NCT02494258 2026-04-02
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
Celgene
Phase 2 Completed
Clinical Trials
63 trialsNCT02467270 2026-03-17
OPTIC
Takeda
Phase 2 Completed
NCT05228470 2026-01-06
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Pfizer
Phase 2 Completed
NCT03578367 2025-11-10
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Novartis
Phase 2 Completed
NCT02158858 2025-10-08
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Constellation Pharmaceuticals
Phase 1/2 Completed
NCT01909934 2025-09-19
Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Takeda
Phase 4 Completed
NCT03066648 2025-05-18
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Novartis
Phase 1 Completed
NCT05819762 2024-12-04
Evaluation of ClearLLab LS Screening Panel
Beckman Coulter, Inc.
Completed
NCT01183949 2024-08-02
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Astex Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01716806 2024-06-11
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
Seagen Inc.
Phase 2 Completed
NCT00457782 2024-04-25
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma
Kyowa Kirin Co., Ltd.
Phase 1 Completed
NCT01063907 2024-04-25
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Kyowa Kirin Co., Ltd.
Phase 1/2 Completed
NCT02124746 2023-06-18
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
Sierra Oncology LLC - a GSK company
Phase 2 Completed
NCT01345019 2022-11-08
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
Amgen
Phase 3 Completed
NCT01667133 2022-06-13
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
Takeda
Phase 1/2 Completed
NCT01423851 2022-03-09
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
NS Pharma, Inc.
Phase 1/2 Completed
NCT03111992 2022-02-09
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma
Novartis
Phase 1 Completed
NCT01777152 2021-11-30
ECHELON-2
Seagen Inc.
Phase 3 Completed
NCT02038036 2021-07-20
RESPONSE-2
Novartis
Phase 3 Completed
NCT02218047 2021-06-01
CONTI-PV
AOP Orphan Pharmaceuticals AG
Phase 3 Completed
NCT02130557 2021-05-18
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Pfizer
Phase 3 Completed
NCT01100502 2021-05-14
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
Seagen Inc.
Phase 3 Completed
NCT00773747 2021-04-30
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02252159 2021-04-26
Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)
Incyte Corporation
Completed
NCT01844765 2021-04-22
DIALOG
Novartis
Phase 2 Completed
NCT01990534 2021-04-09
A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma
Takeda
Phase 4 Completed
NCT01369498 2020-07-01
Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
Gilead Sciences
Phase 2 Completed
NCT01787552 2020-04-15
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
Novartis
Phase 1/2 Completed
NCT01201811 2019-12-05
Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)
Celgene
Phase 4 Completed
NCT02292446 2019-07-18
Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.
Novartis
Phase 3 Completed
NCT01874054 2019-02-12
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
Seagen Inc.
Phase 1/2 Completed
NCT01602952 2018-08-29
Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI
Il-Yang Pharm. Co., Ltd.
Phase 1/2 Completed
NCT01191801 2018-08-22
VALOR
Sunesis Pharmaceuticals
Phase 3 Completed
NCT00607997 2017-06-28
Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia
Sunesis Pharmaceuticals
Phase 2 Completed
NCT01309789 2017-06-28
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
Seagen Inc.
Phase 1 Completed
NCT00866047 2017-03-22
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
Seagen Inc.
Phase 2 Completed
NCT00848926 2017-03-13
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
Seagen Inc.
Phase 2 Completed
NCT00947856 2017-02-02
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Seagen Inc.
Phase 2 Completed
NCT01421667 2016-11-28
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
Seagen Inc.
Phase 2 Completed
NCT01950364 2016-05-11
A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Millennium Pharmaceuticals, Inc.
Phase 1 Completed
NCT01461538 2016-03-04
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Seagen Inc.
Phase 2 Completed
NCT01511289 2016-02-24
Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
Il-Yang Pharm. Co., Ltd.
Phase 3 Completed
NCT02523638 2016-02-17
PEN-PV
AOP Orphan Pharmaceuticals AG
Phase 3 Completed
NCT00435916 2015-01-07
Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
Seagen Inc.
Phase 2 Completed
NCT00528333 2015-01-07
A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
Seagen Inc.
Phase 2 Completed
NCT00079716 2014-12-18
Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma
Seagen Inc.
Phase 1 Completed
NCT00103779 2014-12-18
A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma
Seagen Inc.
Phase 1 Completed
NCT00283101 2014-12-18
A Safety Study in Patients With Chronic Lymphocytic Leukemia
Seagen Inc.
Phase 1/2 Completed
NCT00283114 2014-12-18
A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Seagen Inc.
Phase 1 Completed
NCT00430846 2014-12-18
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
Seagen Inc.
Phase 1 Completed